Table 3. Associations between IHC MIUCB subtypes and clinicopathological features obtained using CK5 and GATA3.
| Clinicopathological features | No (%) | CK5/GATA3 | ||||
|---|---|---|---|---|---|---|
| basal | luminal | double negative | double positive | p | ||
| All cases | 183 (100.0) | 25 (13.7) | 73 (39.9) | 6 (3.3) | 79 (43.1) | |
| Sex | ||||||
| male | 130 (71.0) | 11 (44.0) | 56 (76.7) | 4 (66.7) | 59 (74.7) | 0.014a |
| female | 53 (29.0) | 14 (56.0) | 17 (23.3) | 2 (33.3) | 20 (25.3) | |
| Tumor size* | ||||||
| ≤3.0 cm | 64 (35.4) | 4 (16.0) | 33 (46.5) | 1 (16.7) | 26 (32.9) | 0.028b |
| >3.0 cm | 117 (64.6) | 21 (84.0) | 38 (53.5) | 5 (83.3) | 53 (67.1) | |
| Multifocality | ||||||
| absent | 169 (92.3) | 25 (100.0) | 63 (86.3) | 5 (83.3) | 76 (96.2) | 0.021b |
| present | 14 (7.7) | 0 (0.0) | 10 (13.7) | 1 (16.7) | 3 (3.8) | |
| Tumoral necrosis | ||||||
| absent | 64 (35.0) | 3 (12.0) | 35 (47.9) | 1 (16.7) | 25 (31.6) | 0.005a |
| present | 119 (65.0) | 22 (88.0) | 38 (52.1) | 5 (83.3) | 54 (68.4) | |
| CIS | ||||||
| absent | 109 (59.6) | 18 (72.0) | 36 (49.3) | 4 (66.7) | 51 (64.6) | 0.125a |
| present | 74 (40.4) | 7 (28.0) | 37 (50.7) | 2 (33.3) | 28 (35.4) | |
| Squamous variant | ||||||
| absent | 134 (73.2) | 9 (36.0) | 66 (90.4) | 5 (83.3) | 54 (68.4) | <0.001a |
| present | 49 (26.8) | 16 (64.0) | 7 (9.6) | 1 (16.7) | 25 (31.6) | |
| Glandular variant | ||||||
| absent | 172 (94.0) | 24 (96.0) | 71 (97.3) | 6 (100.0) | 71 (89.9) | 0.199b |
| present | 11 (6.0) | 1 (4.0) | 2 (2.7) | 0 (0.0) | 8 (10.1) | |
| Micropapillary variant | ||||||
| absent | 144 (78.7) | 25 (100.0) | 46 (63.0) | 6 (100.0) | 67 (84.8) | <0.001a |
| present | 39 (21.3) | 0 (0.0) | 27 (37.0) | 0 (0.0) | 12 (15.2) | |
| Sarcomatoid variant | ||||||
| absent | 166 (90.7) | 19 (76.0) | 71 (97.3) | 3 (50.0) | 73 (92.4) | <0.001b |
| present | 17 (9.3) | 6 (24.0) | 2 (2.7) | 3 (50.0) | 6 (7.6) | |
| Plasmacytoid variant | ||||||
| absent | 174 (95.1) | 25 (100.0) | 65 (89.0) | 6 (100.0) | 78 (98.7) | 0.014b |
| present | 9 (4.9) | 0 (0.0) | 8 (11.0) | 0 (0.0) | 1 (1.3) | |
| PTI | ||||||
| absent/low | 91 (49.7) | 5 (20.0) | 37 (50.7) | 3 (50.0) | 46 (58.2) | 0.008b |
| moderate/intense | 92 (50.3) | 20 (80.0) | 36 (49.3) | 3 (50.0) | 33 (41.8) | |
| ITL | ||||||
| absent | 33 (18.0) | 1 (4.0) | 13 (17.8) | 1 (16.7) | 18 (2.8) | 0.001b |
| low/moderate | 131 (71.6) | 15 (60.0) | 58 (79.5) | 4 (66.7) | 54 (68.4) | |
| intense | 19 (10.4) | 9 (36.0) | 2 (2.7) | 1 (16.7) | 7 (8.9) | |
a p value obtained using Pearson’s chi-square test; b p value obtained using likelihood-ratio test. *Tumor size not available in 2 cases. Boldface values are those that are significant (p<0.05). Abbreviations: IHC, immunohistochemical; MIUCB, muscle-invasive urothelial carcinomas of the bladder; CIS, carcinoma “in situ;” PTI, peritumoral inflammation; ITL, intratumoral lymphocytes.